Skip to main content
Clinical Trials/NCT03302208
NCT03302208
Completed
Phase 3

Role of Preoperative Oral Pregabalin in Reducing Inhalational Anesthetic Requirements in Elective Abdominal Hysterectomy Under General Anesthesia: A Randomized Controlled Trial

Nesrine El-Refai1 site in 1 country50 target enrollmentJune 29, 2017

Overview

Phase
Phase 3
Intervention
Pregabalin
Conditions
Hysterectomy
Sponsor
Nesrine El-Refai
Enrollment
50
Locations
1
Primary Endpoint
Inhalational anaesthetic drug requirements
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

In this study the investigators hypothesized that preoperative pregabalin tablet (150 mg orally ) may be effective in reducing intraoperative isoflurane requirements needed to maintain intraoperative hemodynamics within ± 20% of baseline measurement and/or attenuates hemodynamic response to endotracheal intubation in female patients ASA I or II , aged 18-60 years, schedule for elective abdominal hysterectomy surgery under general anesthesia.

Detailed Description

In this study the investigators hypothesized that preoperative pregabalin tablet (150 mg orally ) would be effective in reducing intraoperative isoflurane requirement needed to maintain intraoperative hemodynamics within ± 20% of baseline measurement and/or attenuates hemodynamic response to endotracheal intubation in female patients ASA I or II schedule for elective abdominal hysterectomy surgery under general anaesthesia. The investigators aim to compare the efficacy of preoperative oral pregabalin versus placebo in reducing intraoperative isoflurane requirements needed to maintain intraoperative hemodynamic stability (Blood pressure and heart rate within ± 20% of baseline measurements) in female patients ASA I/II undergoing elective abdominal hysterectomy surgery under general anaesthesia.

Registry
clinicaltrials.gov
Start Date
June 29, 2017
End Date
September 20, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Nesrine El-Refai
Responsible Party
Sponsor Investigator
Principal Investigator

Nesrine El-Refai

professor

Cairo University

Eligibility Criteria

Inclusion Criteria

  • Female patients, aged 18-60 year scheduled for elective abdominal hysterectomy surgery under general anaesthesia.
  • American Society of Anaesthesiology (ASA) physical status I or II.

Exclusion Criteria

  • American Society of Anaesthesiology (ASA) physical status ≥ III.
  • Allergy or hypersensitivity to pregabalin.
  • Patient on calcium channel blocker or anticonvulsant.

Arms & Interventions

pregabalin group

Intervention: Pregabalin

placebo group

Intervention: Placebo

Outcomes

Primary Outcomes

Inhalational anaesthetic drug requirements

Time Frame: an average of 3 hours after induction

Inhalational anaesthetic requirements to maintain hemodynamic stability (± 20% of the baseline) using MAQUET Flow-I anesthetic machine.

Secondary Outcomes

  • pressor response attenuation(an average of 10 minutes after induction)
  • First time for analgesics requirement(postoperative (maximum 6 hours after the end of operation))

Study Sites (1)

Loading locations...

Similar Trials